First National Certificate! DOBOSO Wins Multiple Awards, Continuing to Lead a New Era of Ophthalmic Digital Therapeutics

In the field of myopia control and strabismus-amblyopia treatment, every technological breakthrough means a clearer future for countless children. Recently, DOBOSO (Guangzhou Shijing Medical Treatment Software Co., Ltd.) reached a new milestone: its BeiBeiLe LED myopia treatment device secured China's first national registration certificate under new regulations, while the company also garnered multiple prestigious industry awards.

Regulatory Breakthrough: First National Certificate for LED Red Light Technology

Myopia prevention and control has long been a focal point of societal concern. After years of research and development, DOBOSO's BeiBeiLe LED red light myopia treatment device has officially obtained a medical device registration certificate issued by the Hainan Provincial Medical Products Administration, becoming the "first national certificate" under the new regulatory framework.

What does this mean? It signifies that photobiomodulation (PBM) technology for myopia intervention has received official recognition from national authorities for its safety, efficacy, and clinical compliance. With its precise light wavelength control and ultimate safety protection mechanisms, BeiBeiLe provides a compliant and efficient "new weapon" for myopia prevention and control among Chinese children and adolescents.

Compliance First: New Regulations for Red Light Products

On July 16, 2025, the National Medical Products Administration published the "Guidelines for Classification of Medical Devices for Myopia Control and Amblyopia Treatment Containing Light Sources" on its official website, implementing classified management for red light myopia treatment devices. The guidelines clearly stipulate: red light myopia control products using LED light sources to illuminate the fundus are managed as Class II medical devices; those using laser light sources are managed as Class III medical devices. The classification code has also been clarified—LED light source myopia treatment devices are classified under code 16-03.

Furthermore, the "Expert Consensus on Repetitive Low-Intensity Red Light Irradiation for Adjunctive Treatment of Myopia in Children and Adolescents (2022)" has long pointed out that devices should be selected that have obtained Class II medical device registration certificates from the medical products administration, and that the applicable scope stated in the device instructions should explicitly include adjunctive treatment of myopia.

Therefore, many products on the market—those without Class II medical device registration certificates, those with classification codes that do not meet new regulatory requirements, or those whose registered indications do not explicitly list "adjunctive treatment of myopia"—all suffer from compliance deficiencies. Selling or purchasing these red light products may expose service providers to operational compliance risks, while consumers face safety risks in use.

Industry Recognition: Multiple Prestigious Awards

Beyond its technological breakthroughs, DOBOSO's comprehensive strength has also received widespread acclaim from the industry. Recently, relying on its deep accumulation and outstanding innovation in the field of ophthalmic digital therapeutics, DOBOSO has successively won the "2026 Global Medical Technology · Ophthalmology Application Innovation Award," the "Global Ophthalmology Clinical Application Award," the "2025 Arterial Network Annual Innovation Case," the "VIM 2025 Innovation Award," and recognition as one of the "2025 China Medical Digitalization Top 20 Enterprises."

These substantial awards represent the best affirmation of DOBOSO's commitment to its original mission of "empowering visual health with technology."

DuoBaoShi + BeiBeiLe: Building a Comprehensive Visual Health Ecosystem

From DuoBaoShi, the dichoptic digital therapy that broke through the bottleneck of strabismus-amblyopia treatment, to BeiBeiLe's LED red light technology that ushered in a new era of myopia prevention and control, DOBOSO has built a comprehensive visual health ecosystem covering strabismus-amblyopia rehabilitation and myopia prevention and control.

Behind every cold vision data point is an anxious family. DOBOSO will continue to rely on its strong research and development team and top-tier ophthalmology expert think tank to continuously explore cutting-edge technologies, transforming complex medical principles into digital medical products that children love and parents trust.

The first national certificate is just a new starting point. DOBOSO will continue to deepen its work in ophthalmic digital therapeutics, using the light of technology to illuminate a clear visual world for children.